DEP Phase 3 trials no certainty, page-11

What patient infringement risk? Any company that has commercial partnerships with Pfizer would be in conflict to then partner with us to further develop irinotecan is the risk perhaps. So to avoid conflict of interest partner with a smaller regional country centric company with no ties is the feedback information received from being proactive. Makes sense. They did said they still have no intention of going it alone ”at this stage” have not ruled it out. Unlikely to be required to go through an entire nda so relatively quicker process and if irinotecan being the best prospect, aleady a registered drug. Should be substantially cheeper to put through phase 3? It doesn’t change the drug itself just applying it to the dendrimer scaffold. As I’ve stated before the gov has mechanisms in place to bring promising drugs to market by taking a share in potential future profits or royalties so this too should be put on the table as an option imo? CM is being proactive. I like her. Being negative and suspicious every post following the webinar that has outlined the direction moving forward is ridiculous. Let her plan take shape. She’s only been there 5mths.